BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
22nd October, 2026

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/l, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Outcome of Board Meeting of Beta Drugs Limited-22nd October, 2026

With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 22nd October, 2026, at 9:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has considered and approved the following agenda items:-

1. The un-audited Standalone & Consolidated financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the Quarter & half year ended 30th September, 2026.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following documents:

1. Management Discussion & Analysis.
2. Limited review Report on Consolidated Financial Results alongwith Un-Audited Consolidated Financial Results for the quarter & half year ended 30th September, 2026.
3. Limited review Report on Standalone Financial Results alongwith Un-Audited Standalone Financial Results for the quarter & half year ended 30th September, 2026
4. Certificate as per regulation 33(2)(a) & 33(3)(d) of SEBI (LODR) Regulations, 2015

The meeting of the Board of Directors commenced at 9.00 a.m. and concluded at 11:05 a.m.

This is for your information and appropriate dissemination.

Thanking You

Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited
Rajni
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

BETA DRUGS LIMITED

Management Discussion & Analysis

Beta recorded another strong quarter with impressive performance across its key businesses. Despite global headwinds, the Company demonstrated exceptional operating performance and is on track for a sustained growth in the medium term. Consolidated revenues from operations for the first six months of FY27 grew by 29.20% to INR 263.04 Crs. compared to INR 203.6 Crs. in the same period last year.

The Branded Oncology segment grew by 17%. The growth was impacted by production shutdown due to debottlenecking and capacity expansion at Adley Formulation Plant. Sales were also hampered by supply constraints in platin APIs; consequently, the orders have moved to H2 of FY27. The Company expects to close FY27 Branded Oncology at INR 150 Crs. in line with the guidance. The Branded Oncology segment is poised for a sustained growth of 20%-22% over the medium term supported by accelerated new product launches and stronger brand adoption by oncologists. We have evaluated the recent NPPA notification related to trade margin capping at 30% and are of the view that the recent amendments have no significant bearing on our realisations and / or our margins. We maintain our growth guidance for Branded Oncology and CMO in light of the recent NPPA guidelines

The company's growth was led by a 21% rise in CMO business. The high growth was on the back of new customer additions and inclusion of new products developed by Beta and offered to new and existing customers.

Nivan delivered an exceptional performance in H1FY27, recording a pro-forma growth of 75%. The growth was aided by deeper penetration of key brands and increasing acceptability among prescribers. Nivian's strategy of focused brand building among doctors witnessed stronger traction and the company has entered into marquee IVF chains as a supplier of key products.

Exports segment rebounded in Q2 delivering 95% growth in Q2-FY'27. The Company filed 58 dossiers across select markets of LATAM, MENA, APAC in H1FY27 laying the foundation for future growth. In Derma segment Beta signed an exclusive licensing agreement with Frezyderm for India market for high end cosmeceutical products. API segment witnessed strong growth for H1 FY'27 at 29% with the additional capacity expected to go onstream in Q4FY27.

The Gross margins expanded by 486 basis points to 56.21% in H1FY27 compared to 51.35% in H1FY26. The improvement in Gross Margins is a reflection of higher realisations across businesses. Going forward we expect to maintain the Gross Margin levels through cost reduction efforts which will be supplemented by backward integration at our API plant. Consolidated EBITDA stood at INR 61 Crs. compared to INR 47 Crs. for H1FY26 growing by ~30%. In terms of

margins, the EBITDA margins increased from 23.08% to 23.18% (incl. other income). PAT (excluding minority interest) was at INR 34.3 Crs. in H1FY27 compared to Rs. 23.9 Crs. for the corresponding period last year and INR 41.4 Crs. for the whole of FY26.

The backward integration at the API plant is progressing as per the schedule and the commercial production is expected to commence in Q4FY27. The new capacity and the backward integration are expected to reduce dependency on imports and enable the Company to comply with regulated market guidelines for product registrations. The backward integration is also expected to aid in margin improvement going forward. This will further strengthen the company's ability to produce robust DMFs for regulated markets and facilitate quicker, more effective dossier submissions.

Outlook

The management expects to close FY27 at INR 535+ Crs. for FY27, with EBITDA margins at 23%-24% resulting in a much stronger H2FY27 compared to H1. The Company expects to maintain the growth momentum in Branded Oncology with growth outlook of >20% over the medium term. During H1FY27, the Company launched 4 new products in Branded Oncology of which, 1 was a NDDS and 3 were new formulations, reinforcing our position as the first-to-market company for new products. The company targets to launch atleast 4 more products in H2FY27 including Novel formulations and has a pipeline of 15+ products under development for launch over the next 2 years

In exports segment, the Company is on track to deliver robust consistent growth with commercialisation of approved products. During H1FY27, Beta filed 76 new product dossiers across select export markets taking the total registrations to 415 with more than 800 products under different stages of development and expected to be filed over the next 2 years. For FY27, we expect a growth of 30% driven by existing order book and expected tender wins for our approved products.

At Nivian, we expanded our penetration into IVF chains with sales to organised chains comprising ~25% of total sales. We expect to launch 2 additional products in H2FY27 to propel our growth >50% for FY27. Nivian has considerable room for future expansion as the current doctor coverage is about 60% and the increasing acceptance of Company's brands provide a buoyant growth outlook for the business over the next 2-3 years.

Derma business is expected to rebound in H2FY27 as the redressal of supply chain disruptions make way for higher primary sales leading to accelerated growth through our distribution network. The Company expects to deliver a growth of 20% for FY27 and is on track to achieve the target basis current monthly run rate of INR 2 Crs. The secondary sales for the period H1FY27 has grown by 30% over H1FY26

BETA DRUGS LIMITED

Our investments in R&D and product innovation continue to fuel the growth in oncology at Beta and position the Company as a premier Oncology company. We expect to launch ~15 new products including novel formulations by FY28. The Company actively pursues opportunities that can drive growth and broaden our addressable market whilst remaining steadfast on our strategy to remain a specialty pharmaceutical company focused on oncology and IVF

We have made the investments required for future growth with our current installed capacities sufficient to meet our FY29/30 targets. Our balance sheet remains robust with a net cash of INR 55 Crs. and healthy internal cash generation @50% of EBITDA (OCF).

Our key priorities for capital allocation remain the following:

1. Product registrations for key export markets
2. R&D for new product development and novel formulations
3. Investing in the supply chain efficiencies to improve Nivian's operating margins
4. Opportunistic investments for entry into new areas of oncology including biosimilars
5. Attracting and retaining high quality talent

KHURANA SHARMA & COMPANY
CHARTERED ACCOUNTANTS
H.No. 1299, SECTOR 15-B, CHANDIGARH
PHONE : 9988070254, 9878029920

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Interim Unaudited Consolidated Financial Results for the Quarter and Half-Year ended 30th September, 2026 of Beta Drugs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Interim Unaudited Consolidated Financial Results ("the Statement") of **Beta Drugs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter and half-year ended 30th September, 2026, being submitted by the Parent, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations'). We have initialed the Statement for identification purposes only.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relation
Adley Formulations Private Limited	Indian Subsidiary (wholly owned)
Adley Lab Limited	Indian Subsidiary (wholly owned)
Beta Research Private Limited	Indian Subsidiary (wholly owned)
Nivian Lifesciences Private Limited	Indian Subsidiary (66.09% owned)

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter.

6. The consolidated unaudited financial results include the interim financial information/financial results of Adley Formulations Private Limited, Adley Lab Limited, and Beta Research Private Limited (subsidiaries), which have been reviewed by us in our capacity as statutory auditor. These results also include the interim unaudited financial information/financial results of Nivian Lifesciences Private Limited (subsidiary), whose financial results have been reviewed by another auditor and their report, vide which they have issued an unmodified conclusion, has been furnished to us by the Management. The interim financial information/financial results of all subsidiaries, after consolidation adjustments, reflect a total revenue of Rs.79,36,67,863.69, Total net profit/(loss) after tax of Rs. 14,83,88,065.48 and total comprehensive income / loss of Rs. Nil, for the **quarter ended 30th September, 2026** and a total revenue of Rs.1,48,80,57,489.32, Total net profit/(loss) after tax of Rs. 24,70,70,814.41 and total comprehensive income / loss of Rs. Nil for the **half-year ended 30th September, 2026**. These unaudited financial results have been furnished to us by the management and our opinion on the consolidated financial results, in so far as they relate to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the management and procedures performed by us as stated in paragraph 3 above.

For KHURANA SHARMA & CO.
Chartered Accountants

Signature
(CA VIBHOR KHURANA)
PARTNER
M. NO. 568524
UDIN: 26568524EPJZTH7106

Place: Chandigarh
Date: 22.10.2026

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

Unaudited Consolidated Financial Results for the quarter ended on 30th September' 2026

Particulars	3 Months Ended on 30.09.2026 (Unaudited)	3 Months Ended on 30.06.2026 (Unaudited)	3 Months Ended on 30.09.2025 (Unaudited)	6 Months Ended on 30.09.2026 (Unaudited)	6 Months Ended on 30.09.2025 (Unaudited)	Year Ended on 31.03.2026 (Audited)
I. Revenue From Operations	1,37,48,87,593.50	1,25,54,95,637.62	1,03,38,64,143.07	2,63,03,83,231.12	2,03,59,32,903.25	3,84,82,57,667.32
II. Other Income	1,74,79,576.95	1,58,26,052.52	2,98,76,825.26	3,33,05,629.47	5,97,56,870.79	11,17,96,551.18
III. Total Revenue (I+II)	**1,39,23,67,170.45**	**1,27,13,21,690.14**	**1,06,37,40,968.33**	**2,66,36,88,860.59**	**2,09,56,89,774.04**	**3,96,00,54,218.50**
IV. Expenses						
a) Cost of Materials Consumed	61,80,28,701.42	50,21,69,267.96	46,40,08,135.15	1,12,01,97,969.39	1,04,52,55,070.81	1,73,81,43,501.28
b) Purchase of Stock-in-Trade	-	-	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(1,13,73,538.36)	4,29,95,492.86	2,89,62,813.98	3,16,21,954.50	(5,48,55,285.92)	(2,63,45,192.00)
d) Employee benefit expenses	20,45,44,124.01	20,39,62,612.58	16,48,30,015.53	40,85,06,736.59	32,50,56,029.71	68,00,61,433.74
e) Finance Costs	1,63,98,404.74	2,56,25,047.78	3,61,21,494.89	4,20,23,452.52	6,93,25,483.58	15,31,10,274.33
f) Depreciation & amortisation expenses	4,61,00,981.96	4,34,55,945.35	4,24,01,265.91	8,95,56,927.30	7,96,62,543.63	17,15,28,534.10
g) Other expenses	26,08,84,044.09	23,26,93,765.13	16,29,82,058.87	49,35,77,809.22	31,03,42,601.70	69,96,17,745.86
Total Expenses	**1,13,45,82,717.87**	**1,05,09,02,131.66**	**89,93,05,784.33**	**2,18,54,84,849.53**	**1,77,47,86,443.51**	**3,41,61,16,297.31**
V. Profit before exceptional and extraordinary items and tax (III-IV)	**25,77,84,452.58**	**22,04,19,558.48**	**16,44,35,184.00**	**47,82,04,011.06**	**32,09,03,330.53**	**54,39,37,921.19**
VI.Exceptional Items (Pref. Issue)	-	-	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	**25,77,84,452.58**	**22,04,19,558.48**	**16,44,35,184.00**	**47,82,04,011.06**	**32,09,03,330.53**	**54,39,37,921.19**
VIII.Extraordinary Items	-	-	-	-	-	-
IX. Profit before tax (VII-VIII)	**25,77,84,452.58**	**22,04,19,558.48**	**16,44,35,184.00**	**47,82,04,011.06**	**32,09,03,330.53**	**54,39,37,921.19**
X.Tax Expenses	**6,49,39,714.18**	**5,55,62,303.45**	**4,22,55,730.20**	**12,05,02,017.63**	**8,17,38,162.86**	**12,91,10,952.28**
XI. Profit (Loss) for the period from continuing operations (IX-X)	**19,28,44,738.41**	**16,48,57,255.03**	**12,21,79,453.80**	**35,77,01,993.43**	**23,91,65,167.67**	**41,48,26,968.91**
XII.Profit (Loss) from discounting operations	-	-	-	-	-	-
XIII. Tax expenses of dicounting operations	-	-	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-	-	-
XV. Net Profit/(Loss) for the period before NCI (XI+XIV)	**19,28,44,738.41**	**16,48,57,255.03**	**12,21,79,453.80**	**35,77,01,993.43**	**23,91,65,167.67**	**41,48,26,968.91**
XVI. Non-Controlling Interests	**(73,37,663.58)**	**(68,39,006.75)**	-	**(1,41,76,670.34)**	-	-
XVII. Net Profit/(Loss) for the period after NCI (XV+XVI)	**18,55,07,074.82**	**15,80,18,248.27**	**12,21,79,453.80**	**34,35,25,323.10**	**23,91,65,167.67**	**41,48,26,968.91**
Other comprehensive income						
Items that will not be reclassified to profit or loss						
Gain/(loss) on remeasurement of the defined benefit plans	-	-	-	-	-	(23,69,628.00)
Income tax on above	-	-	-	-	-	5,96,387.98
Items that may be reclassified to profit or loss						
Total Comprehensive Income for the period	**19,28,44,738.41**	**15,80,18,248.27**	**12,21,79,453.80**	**35,77,01,993.43**	**23,91,65,167.67**	**41,66,00,208.94**
XVI. Earning per share						
a) Basic	16.59	14.78	12.10	31.37	23.69	40.92
b) Diluted	16.59	14.78	12.10	31.37	23.69	40.92
XVIII. Paid up equity share captial	**11,12,12,550.00**	**10,68,79,530.00**	**10,09,45,530.00**	**11,12,12,550.00**	**10,09,45,530.00**	**10,13,68,900.00**

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.
2 The company is engaged in single business segment i.e. Pharmaceuticals.
3 Figures are regrouped/rearranged, wherever considered necessary.
4 The consolidated financial results include the unaudited financial results of the subsidiaries: Adley Formulations Pvt Ltd, Adley Lab Limited, Beta Research Pvt. Ltd. and Nivian Lifesciences Private Limited.

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN: 26568524EPJZTH7106
Place : Chandigarh
Date : 22-10-2026

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Unaudited Consolidated Statement of Assets & Liabilities for the year ended on 30th September' 2026

Particulars	As at 30th September' 2026 (Unaudited) Amount in Rs.	As at 31st March' 2026 (Audited) Amount in Rs.
ASSETS		
Non-current assets		
(i) Property, Plant and Equipment	1,19,39,58,907.67	1,15,36,78,960.85
(ii) Intangible assets	1,01,10,85,137.18	9,89,57,670.74
(iii) Capital work-in-progress	8,75,94,052.10	-
(iv) Financial assets	-	
- Investments	-	-
- Loans	-	-
- Other Financial Assets	20,06,16,458.83	17,95,59,538.57
(v) Deferred tax assets (net)	3,03,56,018.32	2,52,26,354.66
(vi) Other non-current assets	24,32,69,635.66	14,89,67,369.46
Total Non-current assets	**2,76,68,80,209.76**	**1,60,63,89,894.28**
Current assets		
(i) Inventories	81,88,80,574.31	74,46,39,389.00
(ii) Financial assets		
- Trade Receivables	1,67,43,46,555.26	1,19,13,09,264.55
- Cash and cash equivalents	1,03,80,46,218.60	1,24,84,79,805.79
- Other Financial Assets	24,20,36,909.06	15,44,94,882.01
(iii) Other Current assets	2,28,78,101.09	1,26,83,230.30
Total current assets	**3,79,61,88,358.32**	**3,35,16,06,571.65**
Total assets	**6,56,30,68,568.08**	**4,95,79,96,465.93**
EQUITY AND LIABILITIES		
Equity		
(i) Equity share capital	11,12,12,550.00	10,13,68,900.00
(ii) Other equity	4,26,58,26,648.97	2,34,63,36,194.95
(iii) Non-controlling interest	37,02,09,017.89	-
Total Equity	**4,74,72,48,216.86**	**2,44,77,05,094.95**
Non-current liabilities		
(i) Financial liabilities		
- Borrowings	27,82,92,748.13	1,33,32,46,519.13
- Other financial liabilities	-	-
(ii) Provisions	2,97,41,506.00	2,81,37,582.00
(iii) Other Non-current liabilities	6,40,05,478.82	6,75,03,346.30
Total Non-current liabilities	**37,20,39,732.95**	**1,42,88,87,447.43**
Current liabilities		
(i) Financial liabilities		
- Borrowings	20,86,01,728.07	14,48,20,656.00
- Trade payables	1,03,45,42,439.42	80,62,78,943.56
- Other financial liabilities	1,21,06,489.54	1,49,59,782.18
(ii) Provisions	10,57,68,979.37	5,74,42,636.87
(iii) Other current liabilities	8,27,60,981.87	5,79,01,904.95
Total Current liabilities	**1,44,37,80,618.27**	**1,08,14,03,923.55**
Total equity and liabilities	**6,56,30,68,568.08**	**4,95,79,96,465.93**

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.

2 The company is engaged in single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN: 26568524EPJ2TH7106
Place : Chandigarh
Date : 22-10-2026

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

For and on Behalf of Board of Directors

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

Unaudited Consolidated Cashflow Statement for the year ended on 30th September' 2026

	Particulars	As at 30th September' 2026 (Unaudited)	As at 31st March' 2026 (Audited)
		Amount in Rs.	Amount in Rs.
A	**CASHFLOW FROM OPERATING ACTIVITIES**		
	Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	**47,82,04,011.06**	**54,39,37,921.19**
	Adjustments for non Cash/Non trade items:		
	Depreciation & Amortization Expenses	8,95,56,927.30	17,15,28,534.10
	Finance Cost	4,20,23,452.52	15,31,10,274.33
	Interest received	(2,92,22,277.91)	(9,86,04,935.91)
	Other inflows/(outflows) of cash	(8,15,68,209.78)	(12,72,40,456.14)
	Operating profits before Working Capital Changes	**49,89,93,903.20**	**64,27,31,337.57**
	Adjusted For:		
	(Increase)/Decrease in trade receivables	(31,48,60,230.56)	(16,55,25,627.92)
	Increase/(Decrease) in trade payables	17,64,81,998.12	9,35,06,395.60
	(Increase)/Decrease in inventories	(2,04,27,786.57)	(14,69,13,503.00)
	Increase/(Decrease) in other current liabilities	1,99,09,720.08	61,07,825.35
	(Increase)/Decrease in short term loans and advances	(7,20,96,547.69)	(6,13,84,441.46)
	(Increase)/Decrease in other current assets	(79,90,852.29)	43,39,417.36
	Net Changes in working capital	**(21,89,83,698.91)**	**(26,98,69,934.07)**
	Net cashflow from Operating Activities (A)	**28,00,10,204.29**	**37,28,61,403.50**
B	**CASHFLOW FROM INVESTING ACTIVITIES**		
	Purchase of tangible/intangible assets	(22,62,67,764.36)	(53,48,16,037.31)
	Interest received	2,92,22,277.91	9,86,04,935.91
	Cash used for Non Current Investments /Acquisition of subsidiary (Nivian)	(20,60,11,958.44)	-
	Cash used for Long Term Loans/Advances	(11,23,60,737.46)	(7,76,96,302.35)
	Net cash used in Investing Activities (B)	**(51,54,18,182.35)**	**(51,39,07,403.75)**
C	**CASHFLOW FROM FINANCING ACTIVITIES**		
	Finance Cost	(4,20,23,452.52)	(15,31,10,274.33)
	Increase in/(Repayment) of Short term Borrowings	2,64,19,313.86	(6,01,17,191.32)
	Increase in/(Repayment) of Long term Borrowings	(1,05,49,53,771.01)	6,33,02,717.91
	Increase in/(Repayment) of Other Long term Liabilities	(44,97,867.48)	(7,88,066.53)
	Increase/ (Decrease) in share capital (excl. non-cash shares issued to Nivian shareholders)	70,06,970.00	4,23,370.00
	Increase/ (Decrease) in share premium	1,09,30,23,197.60	6,95,76,625.80
	Other Inflows/ (Outflows) of cash	-	-
	Net cash used in Financing Activities (C	**2,49,74,390.45**	**(8,07,12,818.47)**
D	**Net Increase/(Decrease) in cash & cash equivalents (A+B+C)**	**(21,04,33,587.61)**	**(22,17,58,818.72)**
E	Cash & Cash equivalents at beginning of period	1,24,84,79,806.00	1,47,02,38,624.51
F	Cash & Cash equivalents at end of period	1,03,80,46,218.39	1,24,84,79,805.79
G	**Net Increase/(Decrease) in cash & cash equivalents (F-E)**	**(21,04,33,587.61)**	**(22,17,58,818.72)**

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN: 26568524EPJZTH7106
Place : Chandigarh
Date : 22-10-2026

For and on Behalf of Board of Directors

RAHUL BATRA	RAJNI BRAR	NIPUN ARORA
MANAGING DIRECTOR	COMPANY SECRETARY	CFO
DIN : 02229234	ACS24684	FCA514044

KHURANA SHARMA & COMPANY
CHARTERED ACCOUNTANTS
H.No. 1299, SECTOR 15-B, CHANDIGARH
PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on Interim Unaudited Standalone Financial Results of Beta Drugs Limited for the Quarter and Half-Year ended 30th September, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Beta Drugs Limited** ("the Company"), for the quarter & half-year ended 30th September, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. We have initialed the Statement for identification purposes only.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting

principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHURANA SHARMA & CO.
Chartered Accountants



Signature
(CA VIBHOR KHURANA)
PARTNER
M. NO. 568524
UDIN: 26568524SMXYBI5214

Place: Chandigarh
Date: 22.10.2026

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

Unaudited Standalone Financial Results for the quarter ended on 30th September' 2026

Particulars	3 Months Ended on 30.09.2026 (Unaudited)	3 Months Ended on 30.06.2026 (Unaudited)	3 Months Ended on 30.09.2025 (Unaudited)	6 Months Ended on 30.09.2026 (Unaudited)	6 Months Ended on 30.09.2025 (Unaudited)	Year Ended on 31.03.2026 (Audited)
I. Revenue From Operations	58,01,10,409.47	55,82,57,842.16	54,48,02,561.23	1,13,83,68,251.63	1,20,80,51,101.64	2,25,42,95,005.63
II. Other Income	1,85,88,897.29	1,86,74,222.35	2,74,34,350.40	3,72,63,119.64	5,71,82,938.93	11,14,33,642.13
III. Total Revenue (I+II)	**59,86,99,306.76**	**57,69,32,064.51**	**57,22,36,911.63**	**1,17,56,31,371.27**	**1,26,52,34,040.57**	**2,36,57,28,647.76**
IV. Expenses						
a) Cost of Materials Consumed	30,32,66,774.99	26,00,36,707.01	29,63,33,580.51	56,33,03,482.00	74,46,55,669.54	1,21,90,63,471.79
b) Purchase of Stock-in-Trade	-	-	-	-	-	-
c) (increase)/Decrease in Stock of Finished Goods/WIP	(1,06,16,557.33)	(19,70,443.16)	3,15,52,145.18	(1,25,87,000.49)	(72,52,351.26)	51,46,085.00
e) Employee benefit expenses	9,40,97,399.23	9,35,68,234.80	8,01,90,278.42	18,76,65,634.03	16,49,89,722.11	33,99,05,865.23
f) Finance Costs	65,09,136.56	1,60,06,075.03	2,97,36,836.68	2,25,15,211.59	5,76,12,001.72	11,80,69,397.56
g) Depreciation & amortisation expenses	2,62,73,511.59	2,48,50,112.26	2,38,19,510.26	5,11,23,623.85	4,42,02,152.68	9,66,93,306.47
h) Other expenses	12,94,34,822.62	10,50,63,648.74	8,93,92,539.81	23,44,98,471.36	18,32,40,046.98	40,47,35,025.58
Total Expenses	**54,89,65,087.66**	**49,75,54,334.68**	**55,10,24,890.87**	**1,04,65,19,422.33**	**1,18,74,47,241.77**	**2,18,36,13,151.63**
V. Profit before exceptional and extraordinary items and tax (III-IV)	**4,97,34,219.10**	**7,93,77,729.83**	**2,12,12,020.76**	**12,91,11,948.94**	**7,77,86,798.80**	**18,21,15,496.13**
VI.Exceptional Items (Pref. Issue)	-	-	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	**4,97,34,219.10**	**7,93,77,729.83**	**2,12,12,020.76**	**12,91,11,948.94**	**7,77,86,798.80**	**18,21,15,496.13**
VIII.Extraordinary Items	-	-	-	-	-	-
IX. Profit before tax (VII-VIII)	**4,97,34,219.10**	**7,93,77,729.83**	**2,12,12,020.76**	**12,91,11,948.94**	**7,77,86,798.80**	**18,21,15,496.13**
X.Tax Expenses	**1,26,15,209.76**	**2,00,42,230.49**	**60,66,122.74**	**3,26,57,440.25**	**2,03,04,863.65**	**3,87,70,370.77**
XI. Profit (Loss) for the period from continuing operations (IX-X)	**3,71,19,009.34**	**5,93,35,499.34**	**1,51,45,898.03**	**9,64,54,508.69**	**5,74,81,935.15**	**14,33,45,125.36**
XII.Profit (Loss) from discounting operations	-	-	-	-	-	-
XIII. Tax expenses of dicounting operations	-	-	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-	-	-
XV. Net Profit/(Loss) for the period (XI+XIV)	**3,71,19,009.34**	**5,93,35,499.34**	**1,51,45,898.03**	**9,64,54,508.69**	**5,74,81,935.15**	**14,33,45,125.36**
Other comprehensive income						
Items that will not be reclassified to profit or loss						
Gain/(loss) on remeasurement of the defined benefit plans	-	-	-	-	-	(21,97,612.00)
Income tax on above	-	-	-	-	-	5,53,094.99
Items that may be reclassified to profit or loss						
Total Comprehensive Income for the period	**3,71,19,009.34**	**5,93,35,499.34**	**1,51,45,898.03**	**9,64,54,508.69**	**5,74,81,935.15**	**14,49,89,642.37**
XVI. Earning per share						
a) Basic	3.29	5.55	1.50	8.84	5.69	14.14
b) Diluted	3.29	5.55	1.50	8.84	5.69	14.14
XVIII. Paid up equity share captial	**11,12,12,550.00**	**10,68,79,530.00**	**10,09,45,530.00**	**11,12,12,550.00**	**10,09,45,530.00**	**10,13,68,900.00**

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.
2 The company is engaged in single business segment i.e. Pharmaceuticals.
3 Figures are regrouped/rearranged, wherever considered necessary.

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN: 26568524SMXYBI5214
Place : Chandigarh
Date : 22-10-2026

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

Unaudited Standalone Statement of Assets & Liabilities for the year ended on 30th September' 2026

Particulars	As at 30th September' 2026 (Unaudited) Amount in Rs.	As at 31st March' 2026 (Audited) Amount in Rs.
ASSETS		
Non-current assets		
(i) Property, Plant and Equipment	68,17,08,650.81	69,08,41,979.39
(ii) Intangible assets	8,66,40,247.76	6,54,88,894.86
(iii) Capital work-in-progress	-	-
(iv) Financial assets	-	
- Investments	75,17,07,631.00	5,77,40,000.00
- Loans	-	-
- Other Financial Assets	24,22,22,468.39	24,36,59,276.15
(v) Deferred tax assets (net)	1,72,94,771.78	1,42,31,257.05
(vi) Other non-current assets	12,33,72,601.96	9,53,86,256.06
Total Non-current assets	**1,90,29,46,371.70**	**1,16,73,47,663.52**
Current assets		
(i) Inventories	34,52,75,908.06	31,41,53,379.00
(ii) Financial assets	-	-
- Trade Receivables	63,74,44,416.01	53,80,53,923.44
- Cash and cash equivalents	98,15,49,148.87	1,18,43,58,516.04
- Other Financial Assets	10,62,96,896.41	13,77,65,422.57
(iii) Other Current assets	86,60,536.99	78,80,681.52
Total current assets	**2,07,92,26,906.34**	**2,18,22,11,922.57**
Total assets	**3,98,21,73,278.05**	**3,34,95,59,586.09**
EQUITY AND LIABILITIES		
Equity		
(i) Equity share capital	11,12,12,550.00	10,13,68,900.00
(ii) Other equity	3,06,66,30,506.67	1,39,42,10,867.06
Total Equity	**3,17,78,43,056.67**	**1,49,55,79,767.06**
Non-current liabilities		
(i) Financial liabilities		
- Borrowings	13,13,61,207.51	1,25,18,70,269.40
- Other financial liabilities	-	-
(ii) Provisions	1,51,82,236.00	1,51,82,236.00
(iii) Other Non-current liabilities	2,17,93,820.90	4,45,03,133.45
Total Non-current liabilities	**16,83,37,264.41**	**1,31,15,55,638.85**
Current liabilities		
(i) Financial liabilities		
- Borrowings	8,07,77,974.86	5,20,02,704.50
- Trade payables	46,44,75,619.46	44,32,06,836.33
- Other financial liabilities	3,97,97,415.70	1,26,65,394.87
(ii) Provisions	1,82,36,166.09	40,33,667.76
(iii) Other current liabilities	3,27,05,780.86	3,05,15,576.72
Total Current liabilities	**63,59,92,956.97**	**54,24,24,180.18**
Total equity and liabilities	**3,98,21,73,278.05**	**3,34,95,59,586.09**

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.
2 The company is engaged in single business segment i.e. Pharmaceuticals.
3 Figures are regrouped/rearranged, wherever considered necessary.

For and on Behalf of Board of Directors

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURA
PARTNER
Membership No. : 568524
UDIN: 26568524SMXYBI5214
Place : Chandigarh
Date : 22-10-2026

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Unaudited Standalone Cashflow Statement for the year ended on 30th September' 2026

	Particulars	As at 30th September' 2026 (Unaudited)	As at 31st March' 2026 (Audited)
		Amount in Rs.	Amount in Rs.
A	**CASHFLOW FROM OPERATING ACTIVITIES**		
	Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	**12,91,11,948.94**	**18,21,15,496.13**
	Adjustments for non Cash/Non trade items:		
	Depreciation & Amortization Expenses	5,11,23,623.85	9,66,93,306.47
	Finance Cost	2,25,15,211.59	11,80,69,397.56
	Interest received	(2,91,59,193.50)	(9,47,00,872.61)
	Other inflows/(outflows) of cash	(2,15,18,456.65)	(4,28,27,609.04)
	Operating profits before Working Capital Changes	**15,20,73,134.22**	**25,93,49,718.51**
	Adjusted For:		
	(Increase)/Decrease in trade receivables	(9,93,90,492.57)	(5,22,60,179.40)
	Increase/(Decrease) in trade payables	2,12,68,783.13	3,77,97,695.23
	(Increase)/Decrease in inventories	(3,11,22,529.06)	(3,97,14,829.00)
	Increase/(Decrease) in other current liabilities	21,90,204.14	3,61,819.10
	(Increase)/Decrease in short term loans and advances	3,14,68,526.16	(1,95,62,001.72)
	(Increase)/Decrease in other current assets	(7,79,855.47)	60,00,421.91
	Net Changes in working capital	**(7,63,65,363.67)**	**(6,73,77,073.88)**
	Net cashflow from Operating Activities (A)	**7,57,07,770.55**	**19,19,72,644.63**
B	**CASHFLOW FROM INVESTING ACTIVITIES**		
	Purchase of tangible/intangible assets	(6,31,41,648.16)	(31,81,81,022.28)
	Interest received	2,91,59,193.50	9,47,00,872.61
	Cash used for Non Current Investments	(69,39,67,631.00)	
	Cash used for Long Term Loans/Advances	(2,65,49,538.14)	(8,95,83,827.96)
	Net cash used in Investing Activities (B)	**(75,44,99,623.80)**	**(31,30,63,977.63)**
C	**CASHFLOW FROM FINANCING ACTIVITIES**		
	Finance Cost	(2,25,15,211.59)	(11,80,69,397.56)
	Increase in/(Repayment) of Short term Borrowings	5,59,07,291.19	(7,80,36,784.38)
	Increase in/(Repayment) of Long term Borrowings	(1,12,05,09,061.89)	1,38,57,294.52
	Increase in/(Repayment) of Other Long term Liabilities	(2,27,09,312.55)	(21,53,595.30)
	Increase/ (Decrease) in share capital	98,43,650.00	4,23,370.00
	Increase/ (Decrease) in share premium	1,57,59,65,130.92	6,95,76,625.80
	Other Inflows/ (Outflows) of cash		
	Net cash used in Financing Activities (C	**47,59,82,486.08**	**(11,44,02,486.92)**
D	**Net Increase/(Decrease) in cash & cash equivalents (A+B+C)**	**(20,28,09,367.17)**	**(23,54,93,819.92)**
E	Cash & Cash equivalents at beginning of period	1,18,43,58,516.05	1,41,98,52,335.96
F	Cash & Cash equivalents at end of period	98,15,49,148.87	1,18,43,58,516.04
G	**Net Increase/(Decrease) in cash & cash equivalents (F-E)**	**(20,28,09,367.17)**	**(23,54,93,819.92)**

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October' 2026.
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.

For and on Behalf of Board of Directors

RAHUL BATRA	RAJNI BRAR	NIPUN ARORA
MANAGING DIRECTOR	COMPANY SECRETARY	CFO
DIN : 02229234	ACS24684	FCA514044

For KHURANA SHARMA & CO.
Chartered Accountants
(FRN : 010920N)

CA VIBHOR KHURANA
PARTNER
Membership No. : 568524
UDIN: 26568524SMXYBI5214
Place : Chandigarh
Date : 22-10-2026

BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
22nd October, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

Scrip:- BETA

Subject:- Certificate as per regulation 33(2) (a) of SEBI (LODR) Regulations, 2015

Dear Sir,

We the undersigned, in our respective capacities as Managing Director and Chief Financial officer of Beta Drugs Limited, certify that the Standalone and Consolidated Unaudited Financial results for the quarter and half year ended 30th September, 2026, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking You
Your's faithfully

For Beta Drugs Ltd.

Rahul Batra
Managing Director
DIN: 02229234

Mr Nipun Arora,
Chief Financial Officer

CIN No.: L24230HP2005PLC028969
Admin. Office : SCO 184, Sector-5, Panchkula-134-114 Haryana (INDIA) Phone. +91-172-2585481-482-483
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
Website :- www.betadrugslimited.com | **E-Mail** :- info@betadrugslimited.com

BETA DRUGS LIMITED

BDL/PKL/SEC/2026-27
22nd October, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

Scrip:- BETA

Subject: Declaration pursuant to Regulation 33 (3) (d) of SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015

Dear Sir/Madam

In accordance with Regulation 33(3) (d) of SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby declare that M/s Khurana Sharma & Company, Chartered Accountant (Firm Registration Number 010920N), statutory Auditors of the company have issued an Auditors Report with unmodified opinion on Standalone and Consolidated Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2026 approved at the Board Meeting held on 22nd October, 2026.

Kindly take the above on your record.

Thanking You
Your's faithfully

For Beta Drugs Ltd.

Rahul Batra
Managing Director
DIN: 02229234

CIN No.: L24230HP2005PLC028969
Admin. Office : SCO 184, Sector-5, Panchkula-134-114 Haryana (INDIA) Phone. +91-172-2585481-482-483
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
Website :- www.betadrugslimited.com | **E-Mail** :- info@betadrugslimited.com